hameln pharma ApS: Financial statements 2023
CVR: 39720213
Source: annual report 2023, Danish Business Authority
01/01/2023 – 31/12/2023
hameln pharma ApS (CVR 39720213) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK 3,130,279 and a net result of DKK 2,324,545 compared with DKK 1,910,112 the year before. That is an increase of 19.8% compared with the year before. Equity in the 2023 report amounted to DKK 7,376,505. The solvency ratio was 47.5%.
- Gross Profit
- DKK 3,130,279
- Profit/Loss
- DKK 2,324,545
- Equity
- DKK 7,376,505
- Total Assets
- DKK 15,534,246
- Employees
- 0
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | - | 3.1 mio. | 2.3 mio. | 7.4 mio. | 0 |
| 2022 | - | 2.6 mio. | 1.9 mio. | 5 mio. | 0 |
| 2021 | - | 1.9 mio. | 1.4 mio. | 3.2 mio. | 0 |
| 2020 | - | 2.4 mio. | 1.9 mio. | 1.8 mio. | 0 |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
As of September 20, 2023, Marina Alexandra Stock has stepped down as director of hameln pharma ApS.
Hameln pharma ApS has published its annual report for 2022. Gross profit came to DKK 2,613,040, and the net result was DKK 1,910,112.
About hameln pharma ApS
hameln pharma ApS is a Danish company of the type Anpartsselskab based in Glostrup, founded in 2018. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The management consists of Frank Jahrand and Stephen Allen Watkin. The company is owned by hameln pharma gmbh. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK 10,300,176 and a net result of DKK 8,050,599 compared with DKK 5,288,671 the year before. Equity in the 2025 report amounted to DKK 20,334,774.